Search

Your search keyword '"François Habersetzer"' showing total 131 results

Search Constraints

Start Over You searched for: Author "François Habersetzer" Remove constraint Author: "François Habersetzer"
131 results on '"François Habersetzer"'

Search Results

1. Single-cell RNA-sequencing of virus-specific cellular immune responses in chronic hepatitis B patients

3. Clinical outcomes after treatment with direct antiviral agents: beyond the virological response in patients with previous HCV-related decompensated cirrhosis

4. Safety and immunogenicity of the therapeutic vaccine TG1050 in chronic hepatitis B patients: a phase 1b placebo-controlled trial

5. Adaptive Immunity to Hepatitis C Virus

6. Hepatitis C virus cell-cell transmission and resistance to direct-acting antiviral agents.

7. Genotype 1 hepatitis C virus envelope features that determine antiviral response assessed through optimal covariance networks.

11. Characteristics and care of chronic hepatitis C treated with direct-acting antivirals in migrants

16. Changes in the profile and therapeutic care of people who use drugs with HCV mono-infection: a retrospective study between 2015 and 2019 from a monocentric tertiary referent center in France

19. Psychiatric disorders and hepatitis C treated with direct-acting antivirals in a French reference center

20. Differences between sporadic hyperplastic gastric polyps and portal hypertensive gastric polyps: a review: a review

22. Predictive Factors for Hepatocellular Carcinoma in Chronic Hepatitis B Using Structural Equation Modeling: A Prospective Cohort Study

23. Sustained Remission After Treatment Withdrawal in Autoimmune Hepatitis: A Multicenter Retrospective Study

24. Origin, HDV genotype and persistent viremia determine outcome and treatment response in patients with chronic hepatitis delta

25. 12 Weeks of a Ribavirin‐Free Sofosbuvir and Nonstructural Protein 5A Inhibitor Regimen Is Enough to Treat Recurrence of Hepatitis C After Liver Transplantation

26. Direct-acting antiviral agent–based regimen for HCV recurrence after combined liver-kidney transplantation: Results from the ANRS CO23 CUPILT study

27. Anticorps anti-pseudo-PCNA de type 1 (anti-SG2NA) : cherchez un cancer, pas le lupus

28. Safe administration of corticosteroids in severe ulcerative colitis and active SARS-CoV2 infection

29. Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial

30. Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment a prospective cohort study

31. HCV-Induced Epigenetic Changes Associated With Liver Cancer Risk Persist After Sustained Virologic Response

32. Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE)

34. Intraabdominal urokinase in the treatment of loculated infected ascites in cirrhosis

35. Impact of age on the characteristics and medical care of chronic hepatitis C patients treated with direct-acting antivirals

36. Impact of Cytomegalovirus Infection on the Outcome of Patients With Cirrhosis: A Preliminary Study

37. RETRACTION: Improved Bone Safety of Tenofovir Alafenamide Compared to Tenofovir Disoproxil Fumarate Over 2 Years in Patients with Chronic HBV Infection

38. Safety of sofosbuvir-based regimens after liver transplantation longitudinal assessment of renal function in the prospective ANRS CO23 CUPILT study

39. A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis

40. Doxorubicin-Loaded Nanoparticles for Patients with Advanced Hepatocellular Carcinoma after Failure of Sorafenib: RELIVE, a Phase-3 Trial

41. FRI-002-Sustained remission after treatment withdrawal in autoimmune hepatitis: A multicenter retrospective study

42. A targeted functional RNA interference screen uncovers glypican 5 as an entry factor for hepatitis B and D viruses

43. Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation

44. Impact of Cytomegalovirus infection on the outcome of patients with cirrhosis: a preliminary study

45. Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients

46. A 2-year multicenter, double-blind, randomized, placebo-controlled study of bezafibrate for the treatment of primary biliary cholangitis in patients with inadequate biochemical response to ursodeoxycholic acid therapy (Bezurso)

47. All-oral combination of ledipasvir, vedroprevir, tegobuvir, and ribavirin in treatment-naïve patients with genotype 1 HCV infection

49. Estimated risk reduction of mortality and transplantation with bezafibrate in patients with PBC and inadequate response to UDCA: application of the UK-PBC and Global PBC risk scores to the BEZURSO trial

50. Impact pronostique de la concentration de 3-hydroxymyristate sur la survie des patients atteints de cirrhose alcoolique ou virale

Catalog

Books, media, physical & digital resources